ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

ELLENCE
Breast cancer
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

ELLENCE Rx

Generic Name and Formulations:
Epirubicin HCl 2mg/mL; soln for IV infusion; preservative-free.

Company:
Pfizer Inc.

Therapeutic Use:

Indications for ELLENCE:

Adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.

Adult:

Give by IV infusion over 15–20 minutes. Administer in repeated 3–4 week cycles for a total of 6 cycles. Total dose may be given on Day 1 of each cycle; or divided equally and given on Days 1 and 8 of each cycle. Initially 100–120mg/m2. Bone marrow dysfunction: consider lower starting dose (75–90mg/m2). Renal or hepatic impairment, dose adjustments: see full labeling.

Children:

Not established.

Contraindications:

Baseline neutrophil count <1500 cells/mm3. Cardiomyopathy and/or heart failure. Recent MI. Severe arrhythmias. Previous treatment with anthracyclines (max cumulative doses). Severe hepatic dysfunction.

Warnings/Precautions:

Cardiovascular disease. Prior or concomitant radiotherapy to mediastinal/pericardial area. Previous anthracycline therapy. Renal or hepatic impairment. Monitor CBCs, platelets, cardiac, renal, and hepatic function before and during each treatment cycle. Consider monitoring serum uric acid, potassium, calcium, phosphate after starting therapy. Avoid extravasation. Elderly (esp. female ≥70yrs). Advise women of child-bearing potential to avoid becoming pregnant during treatment and use effective contraceptive methods. Pregnancy (Cat.D). Nursing mothers: not recommended.

Interactions:

Caution with other cardiotoxic drugs. Avoid concomitant live vaccines. Potentiated by cimetidine; stop cimetidine during therapy. Inflammatory recall reaction possible with previous radiation therapy.

Pharmacological Class:

Anthracycline.

Adverse Reactions:

Myelosuppression (leukopenia, neutropenia, anemia, thrombocytopenia), amenorrhea, lethargy, nausea, vomiting, mucositis, diarrhea, infection, conjunctivitis/keratitis, alopecia, local toxicity, rash/itch; cardiotoxicity, hyperuricemia, acute myelogenous leukemia.

Generic Availability:

NO

How Supplied:

Single-use vials (25mL, 100mL)—1

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs